首页|盐酸西替利嗪滴剂联合孟鲁司特钠咀嚼片治疗小儿咳嗽变异性哮喘的效果及对IgE、IL-4、IL-8水平的影响

盐酸西替利嗪滴剂联合孟鲁司特钠咀嚼片治疗小儿咳嗽变异性哮喘的效果及对IgE、IL-4、IL-8水平的影响

扫码查看
目的 探讨盐酸西替利嗪滴剂联合孟鲁司特钠咀嚼片治疗小儿咳嗽变异性哮喘的效果。方法 选取2020年5月至2022年5月于我院就诊的76例咳嗽变异性哮喘患儿作为研究对象,随机将其分为对照组与观察组,各38例。对照组给予孟鲁司特钠咀嚼片治疗,观察组在对照组基础上加用盐酸西替利嗪滴剂治疗。比较两组的治疗效果、炎性因子水平、肺功能指标及不良反应发生情况。结果 观察组的治疗总有效率为94。74%,显著高于对照组的76。32%,差异具有统计学意义(P<0。05)。治疗前,两组的血清免疫球蛋白E(IgE)、白细胞介素-4(IL-4)及白细胞介素-8(IL-8)水平比较,差异无统计学意义(P>0。05);治疗后,观察组的IgE、IL-4及IL-8水平低于对照组,差异具有统计学意义(P<0。05)。治疗前,两组的最大呼气流速峰值(PEF)、最大呼气中段流量(MMEF25~75)、25%肺活量时最大呼气流量(MEF25)及50%肺活量时最大呼气流量(MEF50)比较,差异无统计学意义(P>0。05);治疗后,观察组的PEF、MMEF25~75、MEF25及MEF50高于对照组,差异具有统计学意义(P<0。05)。观察组的不良反应总发生率为5。26%,显著低于对照组的21。05%,差异具有统计学意义(P<0。05)。结论 盐酸西替利嗪滴剂联合孟鲁司特钠咀嚼片治疗小儿咳嗽变异性哮喘的效果显著,不仅能够有效抑制IgE、IL-4、IL-8水平,还能改善患儿的肺功能,降低不良反应发生率,安全性高,值得推广。
Effect of cetirizine hydrochloride drops combined with montelukast sodium chewable tablets on cough variant asthma in children and its influences on IgE,IL-4 and IL-8 levels
Objective To investigate the effect of cetirizine hydrochloride drops combined with montelukast sodium chewable tablets in the treatment of cough variant asthma in children.Methods A total of 76 children with cough variant asthma who were treated in our hospital from May 2020 to May 2022 were selected as the research objects and randomly divided into control group and observation group,with 38 cases in each group.The control group was treated with montelukast sodium chewable tablets,and the observation group was treated with cetirizine hydrochloride drops on the basis of the control group.The therapeutic effect,levels of inflammatory factors,pulmonary function indexes and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 94.74%,which was significantly higher than 76.32%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in serum immunoglobulin E(IgE),interleukin-4(IL-4)and interleukin-8(IL-8)levels between the two groups(P>0.05);after treatment,the levels of IgE,IL-4 and IL-8 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in peak expiratory flow(PEF),maximal mid-expiratory flow(MMEF25-75),25%maximum expiratory flow(MEF25)and 50%maximal expiratory flow(MEF50)between the two groups(P>0.05);after treatment,the PEF,MMEF25-75,MEF25 and MEF50 in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 5.26%,which was significantly lower than 21.05%in the control group,and the difference was statistically significant(P<0.05).Conclusion Cetirizine hydrochloride drops combined with montelukast sodium chewable tablets in the treatment of cough variant asthma in children has a significant effect.It can not only effectively inhibit the levels of IgE,IL-4 and IL-8,but also improve the lung function of children and reduce the incidence of adverse reactions,which is safe and worthy of promotion.

cetirizine hydrochloride dropmontelukast sodium chewable tabletchildrencough variant asthmainflammatory factor

秦茜、李斌凯

展开 >

商洛市商州区人民医院,陕西商洛,726000

盐酸西替利嗪滴剂 孟鲁司特钠咀嚼片 小儿 咳嗽变异性哮喘 炎性因子

2024

临床医学研究与实践

临床医学研究与实践

ISSN:
年,卷(期):2024.9(19)